Regional Marketing Director, Oncology

Position Overview

• Location Type: Remote
• Employment Type: Full-time
• Salary: Not specified

As a Regional Marketing Director at Corcept, you will play a crucial role in the launch of relacorilaxant in platinum resistant ovarian cancer. You will collaborate with ovarian cancer specialists, gather insights, and contribute to shaping the commercial strategy both before and after FDA approval. This role is part of Corcept’s new Oncology Business Unit, offering an opportunity to build a presence in gynecologic oncology and contribute to the company's growth.

Requirements

• Not specified

Responsibilities

• Develop and lead a thought leader engagement plan within the gynecologic oncology community.
• Identify and develop innovative tactics in collaboration with marketing colleagues.
• Recruit and engage speakers for the bureau and other marketing initiatives, ensuring alignment with brand objectives.
• Collaborate with internal and external partners to build and manage a leading Peer-to-Peer platform, including speaker bureau vendor management, coordinating speaker training, and developing on-label content aligned with brand strategy.
• Drive and monitor Peer-to-Peer program compliance efforts to uphold regulatory standards and best practices.
• Lead the design and execution of an annual insights plan focused on academic, regional, and community thought leaders to inform commercial planning.
• Participate in the development and execution of the overall brand strategy pre-launch and post-launch.
• Develop strategy and lead organizational success at key selected congresses. Establishing and maintaining solid relationships with SGO, GOG, IGCS.
• Foster cross-functional alignment with Corcept leadership to ensure consistent communication and integrated execution.
• Partner closely with commercial teams to ensure strategic execution and achievement of overall brand and business objectives.
• Uphold Corcept’s Key Principle.

Company Information

Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.